New Game Mode. 👀 We just added Rapid Review, a brand new game mode to Rounds. This game mode lets you compete with friends with 1 hint and 1 minute to get as many diagnoses right as you can.

Paroxysmal Nocturnal Hemoglobinuria

Hematology

Illness script · Hematology

Paroxysmal Nocturnal Hemoglobinuria

Acquired clonal stem cell disorder causing GPI-anchor deficiency, leading to complement-mediated intravascular hemolysis, thrombosis, and cytopenias.

This illness script for Paroxysmal Nocturnal Hemoglobinuria covers predisposing factors, classic presentation, mechanism, workup, management, and the clinical pivots that separate it from look-alikes—written for USMLE Step 1 and clerkship reasoning.

Updated Nov 15, 2026All scripts

01

Predisposing factors

  • Young adults (20s–40s); no sex predominance
  • Acquired somatic PIG-A mutation — NOT inherited
  • Strongly associated with aplastic anemia (~50% overlap)
  • May emerge after immune-mediated bone marrow injury
  • No specific environmental triggers; infection/surgery can precipitate attacks

02

Presentation

  • Classic triad: hemolytic anemia, thrombosis, cytopenias
  • Morning dark/cola-colored urine (hemoglobinuria) — classic but present in only ~25%
  • Thrombosis at unusual sites: hepatic (Budd-Chiari), portal, cerebral, mesenteric veins
  • Smooth muscle dystonia: dysphagia, abdominal pain, erectile dysfunction (NO depletion)
  • Fatigue, pallor; pancytopenia if aplastic anemia overlap
  • Symptoms precipitated by infection, surgery, or physiologic stress

03

Pathophysiology

  • Somatic PIG-A mutation in hematopoietic stem cell abolishes GPI-anchor synthesis
  • Loss of GPI-anchored proteins CD55 (DAF) and CD59 (MAC inhibitor) on RBCs and platelets
  • Unregulated terminal complement activation → MAC formation → intravascular hemolysis
  • Free hemoglobin scavenges nitric oxide → smooth muscle dystonia and platelet activation → thrombosis at unusual sites

04

Diagnostics

  • Flow cytometry (gold standard): absent CD55 and CD59 on RBCs and granulocytes
  • CD59 loss on granulocytes most sensitive marker; test both cell lines
  • Hemolysis labs: elevated LDH, indirect bilirubin, low haptoglobin, hemoglobinuria on UA
  • Ham (acidified serum) and sucrose lysis tests — historical, replaced by flow cytometry
  • Bone marrow biopsy if aplastic anemia suspected (hypocellular marrow)

05

Management

  • Eculizumab (anti-C5 complement inhibitor) — first-line for significant hemolysis or thrombosis
  • Ravulizumab — longer-acting C5 inhibitor, dosing every 8 weeks
  • Mandatory meningococcal (+ pneumococcal, Hib) vaccination ≥2 weeks before eculizumab; risk of Neisseria meningitidis
  • Anticoagulation for thrombotic events; consider prophylaxis in high-risk clones
  • Allogeneic stem cell transplant — only cure; reserved for severe disease or aplastic anemia overlap

06

Clinical pivots

How to separate this script from the look-alikes that show up on exams and on the wards.

  • Aplastic Anemia

    PNH shows active hemolysis, thrombosis, and absent CD55/CD59 on flow cytometry; AA has hypocellular marrow without GPI-anchor defect.

  • Autoimmune Hemolytic Anemia

    AIHA has a positive direct Coombs (DAT); PNH is DAT-negative with absent CD55/CD59 on flow cytometry.

  • G6PD Deficiency

    G6PD causes episodic hemolysis triggered by oxidants with Heinz bodies; no thrombophilia and no GPI-anchor defect.

  • Budd-Chiari Syndrome (other causes)

    Spontaneous hepatic vein thrombosis in a young patient without cirrhosis should prompt PNH flow cytometry, not just hypercoagulability panel.

View full library

Educational use only. This illness script is a study framework, not medical advice. Confirm decisions with current guidelines and your clinical supervisors.